<DOC>
	<DOC>NCT02109250</DOC>
	<brief_summary>In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib). The characteristics of patients receiving Caprelsa® (vandetanib) will be described. Therefore real life data regarding demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will be included.</brief_summary>
	<brief_title>CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<criteria>Inclusion criteria The subject population that will be observed in this registry, must fulfil all of the following criteria: 1. Provision of subject Informed Consent 2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic MTC 3. Patients who already received a prescription for vandetanib in accordance with the scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets. The prescription of the medicinal product is clearly separated from the decision to include the subject in the registry. Exclusion criteria Not applicable since patients participating in another study can take part in this registry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Medullary Thyroid Cancer (MTC) vandetanib caprelsa</keyword>
</DOC>